CHRM1 and Alzheimer disease: Integrated network pharmacology and PPI analysis showed these metabolites converge on key AD hubs (ACHE, CHRM1, NOS1, NOS2) and related inflammatory-synaptic nodes, enriched in oxidative-stress response, cholinergic regulation, nitric oxide signaling, and arachidonic-acid metabolism.